ClinicalTrials.gg
CompletedNCT00670241Updated Mar 10, 2025Results posted

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

A Phase 3 interventional study of calcipotriol and betamethasone (LEO 80185 gel) and LEO 80185 vehicle in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
15th of 47
458 · median 200
Started
2008
with 4 others
Phase 3
17 of 47
none open now
Registered
14th of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 15th largest by enrollment, is one of 5 that started in 2008, is one of 17 in phase 3, and was the 14th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

This study will compare efficacy and safety of once daily treatment of calcipotriol plus betamethasone dipropionate gel (LEO 80185) with tacalcitol ointment and LEO 80185 vehicle alone in subjects with psoriasis vulgaris. Subjects will be treated for up to 8 weeks followed by an observation period of up to 8 weeks to investigate the occurence and the time to relapse and occurence of rebound after discontinuation of the investigational products. Only subjects with "controlled disease" will be considered for this observation phase of the study. "Controlled disease" is defined as "Clear" or "Almost Clear" severity category based on Investigator's global assessment (IGA).

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated to be obtained prior to any trial related procedure, including wash-out
  • Clinical diagnosis of psoriasis vulgaris involving trunk and/or arms and/or legs amenable to treatment with a maximum of 100 g of LEO 80185 gel per week or 10 g per day of tacalcitol ointment
  • Disease severity graded moderate, severe or very severe according to the Investigator's global assessment (IGA) of disease severity
  • A minimum PASI score for extent of 2 in at least one body region (i.e.psoriasis affecting at least 10% of arms, and/or 10% of trunk, and/or 10% of legs)
  • Subjects aged 18 years or above
  • Either sex
  • Any ethnic origin
  • Attending hospital outpatient clinic or the private practice of a dermatologist

Exclusion criteria

Exclusion Criteria:

  • Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on psoriasis vulgaris (e.g., alefacept, efalizumab, etanercept, infliximab, adalimumab) within 3 months prior to randomisation
  • Systemic treatment with all other therapies than biologics, with a possible effect on psoriasis vulgaris (e.g., , retinoids, ) within 4 weeks prior to randomisation
  • Systemic treatment with Vitamin D preparations above 500 IU per day
  • PUVA or Grenz ray therapy within 4 weeks prior to randomization
  • UVB therapy within 2 weeks prior to randomisation
  • Any topical treatment of the trunk/limbs (except for emollients) within 2 weeks prior to randomisation
  • Topical treatment for other relevant skin disorders on the face and flexures (e.g., facial and flexural psoriasis, eczema) with potent or very potent (WHO group III-IV) corticosteroids or vitamin D analogues within 2 weeks prior to randomisation
  • Topical treatment for other relevant skin disorders on the scalp (e.g. scalp psoriasis) with very potent (WHO group IV) corticosteroids or vitamin D analogues within 2 weeks prior to randomisation
  • Planned initiation of, or changes to concomitant medication that could affect psoriasis vulgaris (e.g., beta blockers, ACE inhibitors, anti-malaria drugs, lithium) during the study
  • Current diagnosis of erythrodermic, exfoliative or pustular psoriasis
  • Subjects with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atro-phicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds
  • Known or suspected disorders of calcium metabolism associated with hypercalcaemia
  • Known or suspected severe renal insufficiency or severe hepatic disorders
  • Known or suspected to component(s) of the Products
  • Current participation in any other interventional clinical study
  • Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the 4-week period prior to randomisation, except for biologics (3 months)
  • Planned exposure to sun during the study that may affect psoriasis vulgaris
  • Previously randomised to this study
  • Subjects known or suspected of not being able to comply with a trial protocol (e.g. due to alcoholism, drug dependency or psychotic state)
  • Females of wishing to become pregnant during the study, or are breast-feeding, or not using an adequate method of during the study
  • Females of child-bearing potential with positive pregnancy test at Visit 1
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
458 participants (actual)

Study arms

  • Active comparator
    1

    Drug: calcipotriol and betamethasone (LEO 80185 gel)

  • Active comparator
    2

    Drug: Tacalcitol ointment

  • Placebo comparator
    3

    Drug: LEO 80185 vehicle

Interventions

  • Drugcalcipotriol and betamethasone (LEO 80185 gel)

    Drug pages: Calcipotriene · Betamethasone

    Once daily application

  • DrugLEO 80185 vehicle

    Once daily application

  • DrugTacalcitol ointment

    Once daily application

06

What researchers measure

Primary outcomes

  1. Subjects With "Controlled Disease" ("Clear" or "Almost Clear" Disease) According to Investigator's Global Assessment of Disease Severity at Week 8

    Time frame: Week 8

Secondary outcomes

  1. Subjects With "Controlled Disease" According to the Investigator's Global Assessment of Disease Severity at Week 4

    Time frame: Week 4

  2. The Percentage Change in PASI From Baseline to Week 8

    PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8 (worst).

    Time frame: Baseline, Week 4 and 8

  3. Subjects With Relapse During the Study

    Among subjects with controlled disease at week 8 relapse was defined as PASI exceeding the baseline PASI value minus 50% of the reduction in PASI obtained from the baseline visit to the last on-treatment visit

    Time frame: Week 8-16

  4. Subjects With Rebound During the Study

    Time frame: Week 8-16

07

Results

Posted Mar 8, 2011

Participant flow

Participant flow — Overall Study
MilestoneCalcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel Vehicle
Started18318491
Completed17116364
Not completed122127

Outcome measures

PrimarySubjects With "Controlled Disease" ("Clear" or "Almost Clear" Disease) According to Investigator's Global Assessment of Disease Severity at Week 8
Time frame:
Week 8
Reported as:
Number · Participants
Subjects With "Controlled Disease" ("Clear" or "Almost Clear" Disease) According to Investigator's Global Assessment of Disease Severity at Week 8
ParticipantsCalcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel Vehicle
Subjects With "Controlled Disease" ("Clear" or "Almost Clear" Disease) According to Investigator's Global Assessment of Disease Severity at Week 873335
Statistical analysis
  • Calcipotriol Plus Betamethasone Dipropionate Gel vs Tacalcitol Ointment · Cochran-Mantel-Haenszel · p = < 0.001 · Odds ratio (or): 3.42 · 95% CI 2.05 to 5.70
SecondarySubjects With "Controlled Disease" According to the Investigator's Global Assessment of Disease Severity at Week 4
Time frame:
Week 4
Reported as:
Number · participants
Subjects With "Controlled Disease" According to the Investigator's Global Assessment of Disease Severity at Week 4
participantsCalcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel Vehicle
Subjects With "Controlled Disease" According to the Investigator's Global Assessment of Disease Severity at Week 434121
Statistical analysis
  • Calcipotriol Plus Betamethasone Dipropionate Gel vs Tacalcitol Ointment · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 3.51 · 98.33% CI 1.46 to 8.40
SecondaryThe Percentage Change in PASI From Baseline to Week 8

PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8 (worst).

Time frame:
Baseline, Week 4 and 8
Reported as:
Number · Percent change in PASI score
The Percentage Change in PASI From Baseline to Week 8
Percent change in PASI scoreCalcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel Vehicle
The Percentage Change in PASI From Baseline to Week 8-57.0-41.9-17.9
Statistical analysis
  • Calcipotriol Plus Betamethasone Dipropionate Gel vs Tacalcitol Ointment · ANOVA · p = <0.001 · Mean difference (final values): -14.7 · 98.33% CI -22.6 to -6.90
SecondarySubjects With Relapse During the Study

Among subjects with controlled disease at week 8 relapse was defined as PASI exceeding the baseline PASI value minus 50% of the reduction in PASI obtained from the baseline visit to the last on-treatment visit

Time frame:
Week 8-16
Reported as:
Number · participants
Subjects With Relapse During the Study
participantsCalcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel Vehicle
Subjects With Relapse During the Study2873
SecondarySubjects With Rebound During the Study
Time frame:
Week 8-16
Reported as:
Number · participants
Subjects With Rebound During the Study
participantsCalcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel Vehicle
Subjects With Rebound During the Study000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Calcipotriol Plus Betamethasone Dipropionate Gel—0/182 (0%)25/182 (13.7%)
Tacalcitol Ointment—4/184 (2.2%)28/184 (15.2%)
Gel Vehicle—1/91 (1.1%)10/91 (11%)
Most frequent serious events
Most frequent serious events
EventCalcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel Vehicle
Myocardial infarctionCardiac disorders0/1820/1841/91
ArrhythmiaCardiac disorders0/1821/1840/91
GastroenteritisInfections and infestations0/1821/1840/91
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1821/1840/91
Cervical dysplasiaReproductive system and breast disorders0/1821/1840/91
Most frequent other events
Most frequent other events
EventCalcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel Vehicle
PruritusSkin and subcutaneous tissue disorders6/18213/1847/91
NasopharyngitisInfections and infestations11/1826/1841/91
Upper respiratory tract infectionInfections and infestations8/18210/1842/91

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Calcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel VehicleTotal
<=18 years0000
Between 18 and 65 years14815574377
>=65 years35291781
Age, Continuous
Age, Continuous(years)Calcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel VehicleTotal
Mean50.9 ± 14.351.7 ± 13.452.8 ± 14.951.6 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)Calcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel VehicleTotal
Female666938173
Male11711553285
Region of Enrollment
Region of Enrollment(participants)Calcipotriol Plus Betamethasone Dipropionate GelTacalcitol OintmentGel VehicleTotal
Canada18318491458
08

Study locations

1 site
  • Eastern Canada Cutaneous Research Associates Ltd.
    Halifax, Nova Scotia B3H 1Z4, Canada
09

References and documents

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Feb 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2008
First posted
May 1, 2008
Start
Apr 2008
Primary completionActual
Feb 2009
CompletionActual
Apr 2009
Results first posted
Mar 8, 2011
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00670241
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
May 1, 2008
Start date
Apr 2008
Primary completion
Feb 2009
Completion
Apr 2009
Results posted
Mar 8, 2011
Last update
Mar 10, 2025

Study contacts

Richard Langley, MD
principal investigator · Eastern Canada Cutaneous Research Associates Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone

Start the discussion